BING-JIAN FENG portrait
  • Investigator, Huntsman Cancer Institute
  • Faculty, Center for Genomic Medicine
  • Research Associate Professor, Dermatology
801-581-6465

Research Statement

Bing-Jian Feng is a researcher in genomics, proteomics, phenomics, and their clinical applications focusing on cancers and autoimmune diseases. Dr. Feng's laboratory is interested in disease gene hunting, elucidation of disease mechanisms, clinical classification of genetic variants in genetic testing for cancers, clinical biomarker identification, early diagnostic and prognostic test development, and the implementation and dissemination of screening and diagnostic tools in a clinical setting. Dr. Feng develops novel biostatistical methods and design software tools for researchers, clinicians, and genetic counselors. His research focuses on breast cancer, head and neck cancer, Li-Fraumeni syndom, psoriatic arthritis, and psoriasis.

Research Keywords

  • Head and Neck Cancer
  • Breast Cancer
  • Li-Fraumeni Syndrome
  • Variant of Uncertain Significance
  • Clinical Variant Classification
  • Genetic Testing
  • Personalized Medicine
  • Psoriatic Arthritis
  • Psoriasis
  • Prognostic Test
  • Diagnostic Test
  • Proteomics
  • Biomarkers
  • Systematic Biology
  • Genetic Epidemiology
  • Epidemiology
  • Bioinformatics
  • Biostatistics
  • Software Development

Presentations

  • Oral presentation, Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) meeting, Apr 2019, Springdale, US. Invited Talk/Keynote, Presented, 04/12/2019.
  • Oral presentation, 8th Int'l Psoriasis from Gene to Clinic Congress, London, UK. Presentation, Presented, 12/01/2017.
  • Platform presentation, American Society of Human Genetics 67th Annual Meeting, Orlando, FL, USA. Presentation, Presented, 10/10/2017.
  • Platform presentation, American Society of Human Genetics 60th annual meeting: Washington DC, USA. Presentation, Presented, 11/01/2010.
  • Invited keynote speaker, 4th Intl Symposium on Nasopharyngeal Carcinoma: Marrakech, Morocco. Invited Talk/Keynote, Presented, 06/01/2009.
  • Plenary presentation, International Genetic Epidemiology Society (IGES) 17th annual meeting: St Louis, USA. Presentation, Presented, 09/01/2008.

Research/Scholarship Projects

  • Liquid biopsy for Prognosis Prediction and Immune Profiling of head and neck cancers: a pilot study. PI: Bing-Jian Feng. 07/01/2019 - present.
  • Pedigree analysis in clinical genetic testing for cancers. PI: Bing-Jian Feng. 07/01/2019 - present.
  • A stepwise multi-omic approach to the early diagnosis of psoriatic arthritis. PI: Bing-Jian Feng. 07/01/2019 - present.
  • The screening of early biomarkers of psoriatic arthritis. PI: Bing-Jian. 12/01/2018 - present.
  • Hunting for head and neck cancer susceptibility genes by exome sequencing. PI: Mia Hashibe, Sean Tavtigian. 07/01/2018 - present.
  • Translation of genotype and phenotype to precision medicine for psoriatic arthritis. PI: Bing-Jian Feng. 12/01/2017 - present.
  • Genetic variants in the hypoxia pathways and the risk of lung cancer in Nepal. PI: Mia Hashibe (Co-PI Bing-Jian Feng). 06/15/2016 - present.
  • Screening for Missing Heritability of Psoriasis, Psoriatic Arthritis and Sub-phenotypes. PI: Bing-Jian. 02/01/2014 - present.
  • Searching for the causal variants for psoriasis at the MICA/HLA-B locus. PI: Bing-Jian. 04/15/2011 - present.

Software Titles

  • BayesDel. BayesDel is a novel algorithm to predict pathogenicity of genetic variants. BayesDel has been selected by the FDA-recognized ClinGen Expert Panel to be used in the TP53 Rule Specifications for the ACMG/AMP Variant Curation Guidelines. These Guidelines are widely used in genetic testing for Li-Fraumeni Syndrome (a cancer syndrome). BayesDel has been non-exclusively licensed to Ambry Genetics for their clinical operations. Release Date: 03/03/2016.
  • PERCH. PERCH is a framework for the interpretation of genetic variants identified from next-generation sequencing. This software implements a novel deleteriousness score named BayesDel, an improved guilt-by-association algorithm, rare-variant association tests, and a modified linkage analysis. These components are integrated in a quantitative fashion for gene and variant prioritization. This framework is useful for both gene discovery research and clinical genetic testing. PERCH has been non-exclusively licensed to Ambry Genetics for their clinical operations. Release Date: 03/03/2016.

Publications

  • Hart SN (2019). Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. Genetics in Medicine. Published, 01/15/2019.
  • Fortuno C (2018). Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by TP53 variants. Hum Mutat. Published, 08/15/2018.
  • Shimelis H (2018). Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. J Natl Cancer Inst. Published, 08/01/2018.
  • Yishuo Wu (2018). Germline mutations in PPFIBP2 are associated with lethal prostate cancer. Prostate. Published, 07/24/2018.
  • Couch FJ (2017). Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. Published, 09/01/2017.
  • Lanikova L (2017). Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer. Oncotarget. Published, 02/14/2017.
  • Li H (2017). Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genet Med. Published, 01/15/2017.
  • Bing-Jian Feng (2016). PERCH: A Unified Framework for Disease Gene Prioritization. Hum Mutat. Published, 12/12/2016.
  • Young EL (2016). Multigene testing of moderate-risk genes: be mindful of the missense. J Med Genet. Published, 06/15/2016.
  • Meeks HD (2016). BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. Published, 02/15/2016.
  • Li J (2016). Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. J Med Genet. Published, 01/15/2016.
  • Li L (2015). A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. J Med Genet. Published, 05/15/2015.
  • Huang YH (2015). An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiol Biomarkers Prev. Published, 01/15/2015.
  • Tessereau C (2014). Estimation of the RNU2 macrosatellite mutation rate by BRCA1 mutation tracing. Nucleic Acids Res. Published, 08/15/2014.
  • Park DJ (2014). Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. Cancer Discov. Published, 07/15/2014.
  • Southey MC (2013). COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Res. Published, 06/21/2013.
  • Janavičius R (2013). Haplotype analysis and ancient origin of the BRCA1 c.4035delA Baltic founder mutation. Eur J Med Genet. Published, 03/15/2013.
  • Laitman Y (2013). Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet. Published, 02/15/2013.
  • Taherian N (2013). Familial prostate cancer: the damage done and lessons learnt. Nat Rev Urol. Published, 02/15/2013.
  • Thompson BA (2013). Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum Mutat. Published, 01/15/2013.
  • Tsoi LC (2012). Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. Published, 12/15/2012.
  • Eliason MJ (2012). A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol. Published, 10/15/2012.
  • Spurdle AB (2012). BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet. Published, 08/15/2012.
  • Feng B (2012). Descriptive, environmental and genetic epidemiology of nasopharyngeal carcinoma.. Springer and Landes Bioscience. Published, 07/01/2012.
  • Jordan CT (2012). Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet. Published, 05/15/2012.
  • Feng BJ (2011). Design considerations for massively parallel sequencing studies of complex human disease. PLoS One. Published, 07/01/2011.
  • Hamel N (2011). On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet. Published, 03/15/2011.
  • Li Y (2010). Carriers of rare missense variants in IFIH1 are protected from psoriasis. J Invest Dermatol. Published, 12/15/2010.
  • Jia WH (2010). Traditional Cantonese diet and nasopharyngeal carcinoma risk: a large-scale case-control study in Guangdong, China. BMC Cancer. Published, 08/20/2010.
  • Soltani-Arabshahi R (2010). Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol. Published, 07/15/2010.
  • Bei JX (2010). A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. Published, 07/15/2010.
  • Duffin KC (2009). Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J Invest Dermatol. Published, 12/15/2009.
  • Feng BJ (2009). Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa. Br J Cancer. Published, 10/06/2009.
  • Feng BJ (2009). Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet. Published, 08/15/2009.
  • Nair RP (2009). Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. Published, 02/15/2009.
  • Feng BJ (2007). Trend-TDT - a transmission/disequilibrium based association test on functional mini/microsatellites. BMC Genet. Published, 11/01/2007.
  • Feng BJ (2007). Dietary risk factors for nasopharyngeal carcinoma in Maghrebian countries. Int J Cancer. Published, 10/01/2007.
  • Hung RJ (2007). Family history and the risk of kidney cancer: a multicenter case-control study in Central Europe. Cancer Epidemiol Biomarkers Prev. Published, 06/15/2007.
  • Jia WH (2005). Complex segregation analysis of nasopharyngeal carcinoma in Guangdong, China: evidence for a multifactorial mode of inheritance (complex segregation analysis of NPC in China). Eur J Hum Genet. Published, 02/15/2005.
  • Jia WH (2004). Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China. Cancer. Published, 07/15/2004.
  • Feng BJ (2002). Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet. Published, 08/15/2002.